165 related articles for article (PubMed ID: 30996033)
1. Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.
Yang R; Chen H; Guo D; Dong Y; Miller DD; Li W; Mahato RI
J Pharmacol Exp Ther; 2019 Sep; 370(3):864-875. PubMed ID: 30996033
[TBL] [Abstract][Full Text] [Related]
2. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.
Kumar V; Dong Y; Kumar V; Almawash S; Mahato RI
Theranostics; 2019; 9(25):7537-7555. PubMed ID: 31695785
[No Abstract] [Full Text] [Related]
3. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
Wen D; Peng Y; Lin F; Singh RK; Mahato RI
Cancer Res; 2017 Jun; 77(12):3244-3254. PubMed ID: 28428276
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer.
Kumar V; Chaudhary AK; Dong Y; Zhong HA; Mondal G; Lin F; Kumar V; Mahato RI
Sci Rep; 2017 May; 7(1):1665. PubMed ID: 28490735
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment.
Bariwal J; Kumar V; Chen H; Bhattarai RS; Peng Y; Li W; Mahato RI
J Control Release; 2019 Sep; 309():231-243. PubMed ID: 31330213
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
7. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma.
Kumar V; Wang Q; Sethi B; Lin F; Kumar V; Coulter DW; Dong Y; Mahato RI
Biomaterials; 2021 Nov; 278():121138. PubMed ID: 34634662
[TBL] [Abstract][Full Text] [Related]
8. Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
Lin F; Wen D; Wang X; Mahato RI
Biomaterials; 2019 Feb; 192():95-108. PubMed ID: 30447399
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
[TBL] [Abstract][Full Text] [Related]
11. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
12. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
13. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
14. Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells.
Gupta S; Weston A; Bearrs J; Thode T; Neiss A; Soldi R; Sharma S
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):349-357. PubMed ID: 27349498
[TBL] [Abstract][Full Text] [Related]
15. Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA.
Kang Y; Lu L; Lan J; Ding Y; Yang J; Zhang Y; Zhao Y; Zhang T; Ho RJY
Acta Biomater; 2018 Mar; 68():137-153. PubMed ID: 29288085
[TBL] [Abstract][Full Text] [Related]
16. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
17. Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
Wang Z; Ravula R; Shi L; Song Y; Yeung S; Liu M; Lau B; Hao J; Wang J; Lam CW; Chow MS; Huang Y
Oncotarget; 2016 Sep; 7(38):61246-61261. PubMed ID: 27487134
[TBL] [Abstract][Full Text] [Related]
18. A Novel MPEG-PDLLA-PLL Copolymer for Docetaxel Delivery in Breast Cancer Therapy.
Tan L; Peng J; Zhao Q; Zhang L; Tang X; Chen L; Lei M; Qian Z
Theranostics; 2017; 7(10):2652-2672. PubMed ID: 28819454
[TBL] [Abstract][Full Text] [Related]
19. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
20. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
